The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapies for the Treatment of Intermediate and Advanced Hepatocellular Carcinoma Unsuitable for Transarterial Chemoembolization

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer. 2020;9(6):682–720. doi:10.1159/000509424
   PubMed Web of Science ®Google Scholar
• Villanueva A, Longo DL. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Kudo M, Han KH, Ye SL, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements. Liver Cancer. 2020;9(3):245–260. doi:10.1159/000507370
   PubMed Web of Science ®Google Scholar
• Yue R, Liu X. Impact of transarterial chemoembolization or hepatic artery infusion chemotherapy on liver function after hepatocellular carcinoma resection: an observational study. Digestion. 2023;1–8. doi:10.1159/000528750
   Web of Science ®Google Scholar
• Chen S, Yuan B, Yu W, et al. Comparison of arterial infusion chemotherapy and chemoembolization for locally advanced hepatocellular carcinoma: a multicenter retrospective study. J Gastrointest Surg. 2022;26(11):2292–2300. doi:10.1007/s11605-022-05421-x
   PubMed Web of Science ®Google Scholar
• An C, Zuo M, Li W, et al. Infiltrative hepatocellular carcinoma: transcatheter arterial chemoembolization versus hepatic arterial infusion chemotherapy. Front Oncol. 2021;11:747496. doi:10.3389/fonc.2021.747496
   PubMed Web of Science ®Google Scholar
• Hu J, Bao Q, Cao G, et al. Hepatic arterial infusion chemotherapy using oxaliplatin plus 5-fluorouracil versus transarterial chemoembolization/embolization for the treatment of advanced hepatocellular carcinoma with major portal vein tumor thrombosis. Cardiovasc Intervent Radiol. 2020;43(7):996–1005. doi:10.1007/s00270-019-02406-3
   PubMed Web of Science ®Google Scholar
• Zheng K, Zhu X, Fu S, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial. Radiology. 2022;303(2):455–464. doi:10.1148/radiol.211545
   PubMed Web of Science ®Google Scholar
• He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953–960. doi:10.1001/jamaoncol.2019.0250
   PubMed Web of Science ®Google Scholar
• Lyu N, Wang X, Li JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, Phase III trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468–480. doi:10.1200/JCO.21.01963
   PubMed Web of Science ®Google Scholar
• Ueshima K, Ogasawara S, Ikeda M, et al. Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma. Liver Cancer. 2020;9(5):583–595. doi:10.1159/000508724
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, Phase 2–3 study. Lancet Oncol. 2021;22(7):977–990. doi:10.1016/S1470-2045(21)00252-7
   PubMed Web of Science ®Google Scholar
• Huang J, Zhong B, Jiang N, et al. Transarterial chemoembolization combined with immune checkpoint inhibitors plus tyrosine kinase inhibitors versus immune checkpoint inhibitors plus tyrosine kinase inhibitors for advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:1217–1228. doi:10.2147/JHC.S386672
   PubMed Web of Science ®Google Scholar
• Zhu HD, Li HL, Huang MS, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8(1):58. doi:10.1038/s41392-022-01235-0
   PubMed Web of Science ®Google Scholar
• J LB, Gao S, Zhu X, et al. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy. 2021;13(17):1395–1405. doi:10.2217/imt-2021-0192
   PubMed Web of Science ®Google Scholar
• Lai Z, He M, Bu X, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, Phase II trial. Eur J Cancer. 2022;174:68–77. doi:10.1016/j.ejca.2022.07.005
   PubMed Web of Science ®Google Scholar
• Li S, Lyu N, Han X, et al. Hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: a propensity score-matching analysis. J Vasc Interv Radiol. 2021;32(9):1267–1276. doi:10.1016/j.jvir.2021.06.008
   PubMed Web of Science ®Google Scholar
• Chen CB, Chen CM, Tzeng RH, et al. Combining HAIC and sorafenib as a salvage treatment for patients with treatment-failed or advanced hepatocellular carcinoma: a single-center experience. J Clin Med. 2023;12(5). doi:10.3390/jcm12051887
   Web of Science ®Google Scholar
• Huang Y, Zhang L, He M, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus sorafenib for hepatocellular carcinoma refractory to transarterial chemoembolization: retrospective subgroup analysis of 2 prospective trials. Technol Cancer Res Treat. 2022;21:2081108019. doi:10.1177/15330338221117389
   Web of Science ®Google Scholar
• Li Q, He M, Chen H, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized Phase III trial. J Clin Oncol. 2022;40(2):150–160. doi:10.1200/JCO.21.00608
   PubMed Web of Science ®Google Scholar
• Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy. Liver Cancer. 2015;4(3):188–199. doi:10.1159/000367746
   PubMed Web of Science ®Google Scholar
• Mei J, H LS, J LQ, et al. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:167–176. doi:10.2147/JHC.S298538
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang K, Liu C, et al. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study. Front Immunol. 2023;14:1127349. doi:10.3389/fimmu.2023.1127349
   PubMed Web of Science ®Google Scholar
• Luo L, Xiao Y, Zhu G, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a tertiary medical center experience. Front Oncol. 2022;12:1004652. doi:10.3389/fonc.2022.1004652
   PubMed Web of Science ®Google Scholar
• He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021;13:17552544. doi:10.1177/17588359211002720
   Web of Science ®Google Scholar
• Mei J, Tang YH, Wei W, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma. Front Oncol. 2021;11:618206. doi:10.3389/fonc.2021.618206
   PubMed Web of Science ®Google Scholar
• Lyu N, Kong Y, Pan T, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin in hepatocellular cancer with extrahepatic spread. J Vasc Interv Radiol. 2019;30(3):349–357. doi:10.1016/j.jvir.2018.09.004
   PubMed Web of Science ®Google Scholar
• Santagata S, Rea G, Castaldo D, et al. Hepatocellular carcinoma (HCC) tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) tumor microenvironment. Hepatol Int. 2023. doi:10.1007/s12072-023-10537-6
   PubMed Web of Science ®Google Scholar
• Long HY, Huang T-Y, Xie X-Y, et al. Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World J Clin Cases. 2021;9(21):5754–5768. doi:10.12998/wjcc.v9.i21.5754
   PubMed Web of Science ®Google Scholar
• Chen H, Zhou XH, Li JR, et al. Neutrophils: driving inflammation during the development of hepatocellular carcinoma. Cancer Lett. 2021;522:22–31. doi:10.1016/j.canlet.2021.09.011
   PubMed Web of Science ®Google Scholar
• Zhu H, Feng J, Xiang Y, et al. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors. BMC Cancer. 2023;23(1):547. doi:10.1186/s12885-023-11003-0
   PubMed Web of Science ®Google Scholar
• Zhang L, Feng J, Kuang T, et al. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: a pooled analysis of 44 retrospective sudies. Int Immunopharmacol. 2023;118:110019. doi:10.1016/j.intimp.2023.110019
   PubMed Web of Science ®Google Scholar
• Tajiri K, Kawai K, Minemura M, et al. Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil. Hepatol Res. 2015;45(7):755–763. doi:10.1111/hepr.12417
   PubMed Web of Science ®Google Scholar
• Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61(2):318–324. doi:10.1016/j.jhep.2014.03.030
   PubMed Web of Science ®Google Scholar
• Shimose S, Iwamoto H, Niizeki T, et al. Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study. Cancers. 2020;12(7):1867. doi:10.3390/cancers12071867
   PubMed Web of Science ®Google Scholar
• Ng K, Tan J, Tan JJE, et al. Impact of immune-related adverse events on efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma. Liver Cancer. 2022;11(1):9–21. doi:10.1159/000518619
   PubMed Web of Science ®Google Scholar
• Chen CT, Liu TH, Shao YY, Liu KL, Liang PC, Lin ZZ. Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma. Int J Mol Sci. 2021;22(23). doi:10.3390/ijms222312880
   Web of Science ®Google Scholar